Date Title Description PDF
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
23 Nov 2022 On business and financial situation The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day   Download
04 Nov 2022 On business and financial situation The Company releases the press release related to the first nine months of 2022 financial results Download
04 Nov 2022 On business and financial situation The Company releases the first nine months 2022 financial results presentation Download
15 Mar 2022 On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download

Pages

Date Title Description PDF
17 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 January 2022 and 14 January 2022 Download
10 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 January 2022 and 7 January 2022 Download
03 Jan 2022 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 27 December 2021 and 31 December 2021 Download
28 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 Download
20 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages